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OBJECTIVES: The EQ-5D is the most used questionnaire to obtain utilities. Because
of its index ceiling effect, Tobit and CLAD-CQR (Censored Least Absolute Deviations
– Censored Quantile Regression) models are often used instead of Ordinal Least
Squares for its modelization. CLAD models are usually presented as a robust alter-
native to the Tobit misspecification problems in presence of heteroskedasticity.
The aim of this study is to evaluate the suitability of the CLAD-CQR models for the
estimation of utilities and QALYs (Quality-Adjusted Life Years), to evaluate the
impact of different chronic conditions in Catalan population’s health. METHODS:
The EQ-5D was interview-administered in the 2006 Catalan Health Interview Sur-
vey, a cross-sectional study of a representative sample of the non-institutionalised
general population (n15,926). As well as CLAD-CQR, Tobit model was adjusted to
assess utility losses associated with 15 chronic conditions. Goodness of fit was
assessed by cross-validation (Mean Square Error –MSE-, Mean Absolute Deviations
–MAD-). RESULTS: As ceiling effect was over 50%, CQR models on the 30 percentile
had to be applied instead of CLAD models on the median. CQR showed a slightly
worse fit to data (MSE0.084, MAD0.246) than Tobit (MSE0.068, MAD0.218).
The impact of the different chronic conditions measured in QALYs obtained from
the CQR was on average around 70% larger than the ones of the Tobit model.
CONCLUSIONS: Tobit and CLAD-CQR model latent quality of life, not anchored in
0death and 1perfect health. While Tobit allows an estimation of observed util-
ities and marginal effects, interpretable as QALYs, CQR do not in the case of right-
censoring. This leads to overestimation of effects and makes CLAD-CQR models
inappropriate for obtaining QALYs, just as the untransformed Tobit’s latent vari-
able. Moreover, the suitability of modelling percentiles differing from the median
should be discussed.
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OBJECTIVES: Regulators of medical technologies are facing increasing pressure to
make their deliberations concerning the benefits and risk more transparent. Both
benefits and risks are often measured via multiple competing outcomes. Hence,
MCDA models like the Analytic Hierarchy/Network Process are valuable tools in
quantifying decision trade-offs. The objective of this paper is to demonstrate the
use of MCDA models for benefit-risk assessment and the use of sensitivity analysis
to assess the impact of uncertainty and patient heterogeneity.METHODS:Using an
existing data set about anti-depressants we construct a decision model for use with
AHP weights, including clinical endpoints, adverse events and quality of life. AHP
priorities for the main criteria (benefits and risks) were obtained from the general
public (n15) using face–to-face interview. After base-case analysis of decision
trade-offs, three forms of sensitivity analysis for MCDA models were employed.
RESULTS: We applied three forms of sensitivity analysis, including 1) manual ad-
justment of criteria weights using a slider; 2) probabilistic sensitivity analysis (PSA)
of the criteria weights; and 3) PSA of the expected drug performance on each of the
criteria. Examples will be graphically presented and discussed. CONCLUSIONS:
One of the advantages of AHP/ANP is its ease of use. However, in order to make
judgments about benefits and risks decision makers, may wish to generalize to a
wider population and as well as to quantify decision trade-offs in subgroups of
patients. The methods employed provide this flexibility. However, the strategy
chosen should not be more complex than necessary to support the decision maker.
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OBJECTIVES: It is becoming increasingly common that early stage drug candidates
have potential applications in several therapy areas. This is especially prevalent
where several diseases share a similar aetiology. Areas such as immunology, on-
cology and metabolic disorders can have ailments that are characterised by differ-
ent physiological involvement but share a similar underlying cause. The objective
of this study was to model the impact of a multiple indication launch on drug
revenue over time, as well as develop a tool to enable launch strategy scenario
testing. METHODS: The attractiveness and potential NPV of each therapy area is
assessed using a combination of qualitative and quantitative methods. Therapy
areas are scored and ranked by defined metrics allowing the optimum therapy area
to be selected as the first launch indication. The assessment is repeated for the
remaining therapy areas to account for changes in pricing dynamics from the
initial launch indication, to generate the next most attractive therapy area and so
on. NPV for the drug is then calculated based on a trade-off between patient pop-
ulation size and pricing dynamics across indications. RESULTS: In general, the
larger patient populations translate into lower drug costs to meet with budget
impact thresholds. It is therefore vital for manufacturers to understand the optimal
trade-off between price and population size across indications in order to maxi-
mise the overall commercial potential of a drug. When different indications have
significantly differently sized patient populations, drug pricing becomes an issue.
The research concluded that if the correct strategy is employed, a drug launch
strategy can be optimised to generate the maximum possible revenue over the
greatest number of indications. CONCLUSIONS: Modeling changes in price and
population size during multiple-indication launches can be a vital tool in under-
standing total revenue potential of a new product, and optimal launch sequencing.
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OBJECTIVES:To compare three methods of measuring multimorbidity according to
the use of health resources (cost of care) in primary health care (PHC). METHODS:
Design: retrospective study using computerized medical records. Setting: thirteen
PHC teams in Catalonia (Spain). Participants: assigned patients requiring care in
2009. Main measurements: the socio-demographic variables, co-morbidity and
costs. Methods of comparison were: a) Combined Comorbidity Index (CCI): an index
itself was developed from the scores of acute and chronic episodes; b) Charlson
Index (ChI); and c) Adjusted Clinical Groups case-mix: resource use bands (RUB).
The cost model was constructed by differentiating between fixed (operational) and
variable costs. Statistical analysis: was developed 3 multiple lineal regression mod-
els to assess the explanatory power of each measure of co-morbidity were com-
pared from the of determination coefficient (R2), p0.05. RESULTS: A total fo
227,235 patients were included. Woman: 55.6%, average age was 44.1 years, mean
episodes/year: 4.5; average visits/patient/year: 8.1, the mean unit of cost was
€654.2. The CCI explained a R250.4%, the ChI a R229.2% and RUB a R239.7% of
the variability of the cost. The ICC is acceptable behaviour, albeit with low scores (1
to 3 points), showed no conclusive results. CONCLUSIONS: The CCI may be a sim-
ple method of predicting PHC costs in routine clinical practice. If confirmed, these
results will allow improvements in the comparison of the case-mix.
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OBJECTIVES: When evaluating healthcare interventions, decision-makers are in-
creasingly asked to consider multiple criteria to support their decision. The MCDA-
based EVIDEM framework was developed to support this process. It includes a
simple weight elicitation technique, designed to be easily applicable by a broad
range of users. The objective of this study was to compare the EVIDEM technique
with more traditional techniques. METHODS: An online questionnaire was devel-
oped comparing the EVIDEM technique with four alternative techniques including
AHP, best/worst scaling, ranking and point-allocation. A convenience sample of 60
Dutch and Canadian students were asked to fill out the questionnaires as if they
were sitting in an advisory committee for reimbursement/prioritization of health-
care interventions. They were asked to provide weights for 14 criteria using two
techniques, and to provide feedback on ease of use and clarity of concepts of the
different techniques. RESULTS: Results based on the first 30 responses show that
EVIDEM is easy to understand and takes little time to complete, three minutes on
average. Criteria weights derived using the EVIDEM technique and best/worst scal-
ing are divergent. Comparing the rank order of criteria respondents gave using
these two techniques; there is more resemblance in rank order of criteria weighted
with the EVIDEM technique. Compared to AHP/ranking/point-allocation, EVIDEM
takes less time to complete but is only preferred by 33% of decision-makers. AHP/
ranking and point allocation were often described as clearer and more reflective of
the respondents’ opinion. CONCLUSIONS: The simple technique is proposed as a
starting point for users wishing to adapt the EVIDEM framework to their own con-
text. Other techniques may be preferred and their impact on the MCDA value
estimate generated by applying the framework is being explored. This project is
part of a large collaborative work that includes developing and validating this
framework to facilitate sound and efficient MCDA-applications.
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OBJECTIVES: Personalized medicine (PM) takes into account that diagnostic and
therapeutic health technologies should be based on individual characteristics of
patients such as risk profile and treatment response. Health policy decisions under
constrained resources in PM require adequate evaluation methods that incorpo-
rate economic aspects and multiple characteristics (e.g., genotypes, blood mark-
ers). Microsimulation is a technique to evaluate health technologies, policies and
interventions based on individual characteristics. Our goal was to identify and
contrast different microsimulation approaches and discuss the applicability of
these approaches in the evaluation of PM. METHODS: We performed a review on
microsimulation and applications in social sciences, health care and politics. As-
sessment criteria include the modeling of patient characteristics/patient history/
prior events, the way events or transitions between health states are modeled, the
inclusion of life years/utilities/costs, open/closed cohort approach, and the way
time is modeled.RESULTS: Identified approaches range from state-transition mod-
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els, discrete-event-simulation models to equation-based models. Individual char-
acteristics relevant for PM include individual risk factors, clinical properties, pa-
tient history, severity of disease, number of repeated events. Different approaches
were used to link risk factors and predictors to prognosis and treatment decisions
and success as well as resource use. E.g., POHEM is a leading Canadian microsimu-
lation for health care policies. Applications range from lung cancer treatment,
breast cancer prevention to the evaluation of cardiovascular diseases. To support
decisions on HIV prevention Rauner et. al. built a discrete-event-simulation where
breast feeding mothers are even linked to their children. Overall microsimulation
has been successfully applied e.g., in cancer research, chronic diseases or screen-
ing and prevention. CONCLUSIONS: Microsimulation techniques are broadly ap-
plied but still underrepresented in economic evaluations for health care policies.
Microsimulation is a powerful tool for evaluating PM-strategies, because it can be
used to incorporate the genetic and clinical heterogeneity of individuals as well as
personalized decision algorithms.
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OBJECTIVES: In 2009, the cost-effectiveness of drugs for chronic myeloid leukae-
mia for use in the UK NHS was evaluated by the National Institute of Health and
Clinical Excellence (NICE). Two questions were considered: a) dasatinib vs. nilotinib
vs. high-dose imatinib vs. interferon-alpha for imatinib-resistant patients, and b)
dasatinib vs. nilotinib vs. interferon-alpha for imatinib-intolerant patients. Here,
three methodological issues are discussed which strongly influenced the cost-
effectiveness of these drugs. These issues are also important in estimation of the
cost-effectiveness of many other drugs and other health technologies. METHODS:
1) Overall survival: Several methods were considered for estimating overall sur-
vival, including those used by the drug sponsors, Novartis and Bristol-Myers
Squibb; 2) Sources of mortality: Two approaches were considered: a) split by mor-
tality due to chronic myeloid leukaemia and general mortality or b) both combined;
3) Treatment duration: This was reported in none of the trials. Several methods of
estimating treatment duration were considered. RESULTS: 1) Overall survival: It
was not possible to extrapolate overall survival because it was very immature in
the trials. Instead, the preferred method was estimation via a surrogate relation-
ship using major cytogenetic response; 2) Sources of mortality: Option (a) was
preferred; and 3) Treatment duration: the preferred method was by reference to
mean progression-free survival, adjusted for treatment cessation due to adverse
events. CONCLUSIONS: To estimate the cost-effectiveness of health technologies
for a variety of conditions, it is recommended that 1) if overall survival from a trial
is immature, it can be estimated by surrogate relationships; 2) for chronic condi-
tions, the analyst should consider modelling separately disease-specific mortality
and general mortality; and 3) for drugs, the mean number of doses in clinical trials
should be reported so that it is not necessary to estimate this important informa-
tion using indirect methods.
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OBJECTIVES: Objective of the SCAN project is to support pharma companies in
Italy, in managing the complexity of the new drugs pricing process approval at both
National and regional level, by identifying a fair price based on the real new drug
value. The rationale behind SCAN is first to analyze in a structured and evidence
based way all benefits related to a new drug vs a comparator, from clinical to
pharmacoeconomic point of view, and then to get a fair price weighting all benefits
with a National Board of expert who validate the whole process and result.
METHODS: SCAN is an integrated method of data analysis, software platform and
expert opinion, where all the required market access tools are linked: marketing
forecasts, market analysis and budget impacts at both National and Regional level.
Added value of the platform is the value-based pricing that determines the price of
the new drug based on its added value (ie efficacy, safety) compared to the standard
of care for a certain disease, validated by a multidisciplinary National Board of
expert, made of pharmacologists, pharmacoeconomists and clinicians. Some trials
have been done comparing lapatinib (that has recently got the price in the meta-
static breast cancer indication from the National Drug Agency) versus
trastuzumab. RESULTS: The price obtained with the software simulations pro-
duced a value-based ex factory price/pack of 1500€, compared to 1225€ determined
by the Italian National Agency (AIFA). CONCLUSIONS: The performed simulation
shows that the system is a robust tool to determine a value based price which takes
into account the innovativeness of the drug.
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OBJECTIVES: To develop a flexible and generic economic model quantifying poten-
tial savings associated with Rx-to-OTC switches from the perspective of European
policy makers and health care budget holders. METHODS: A systematic review of
the literature of Rx-to-OTC switches was performed to understand the populations
involved, key drivers of economic benefits and the factors impacting these. To
ensure applicability across Europe, health care settings were analysed for the UK,
France, Germany, Italy, Spain and Poland. Experts were consulted to validate the
model structure and assumptions.RESULTS:A budget impact framework was used
and the model was developed primarily for acute conditions. The model considers
six patient groups which may initiate the switched-to-OTC drug: those on the Rx
drug, other Rx drugs, OTC-treated, untreated, and undiagnosed (OTC-treated and
untreated). From the budget holder perspective, the model includes savings due to
avoided: Rx drug acquisition, doctor’s visits to obtain a prescription and emergency
room visits or hospitalisations due to easier access to an effective or safer therapy.
The policy-maker perspective also includes employers’ benefits, such as less time-
off work to obtain a prescription and less absenteeism & presenteeism due to easier
access to therapies that improve employee productivity. The algorithm to estimate
cost consequences of potential adverse events due to lack of doctor’s supervision
was developed. The model has a 5-year time horizon with a function to conduct an
analysis for one year which may represent the savings at the forecast peak uptake.
An option to estimate the consequences of the disreimbursement policies was
incorporated. The model is particularly sensitive to uptake rates across different
groups of patients. The model is flexible and easily adaptable to different acute
conditions and countries in Europe. CONCLUSIONS: The economic impact associ-
ated with Rx-to-OTC switches can be credibly estimated in Europe. Preliminary
analyses suggest that such switches are cost-saving.
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OBJECTIVES: There is currently no consensus on the appropriate method to esti-
mate utilities for joint health conditions. We reviewed the literature to understand
reasons for differences in conclusions drawn and to identify where further re-
search is required. METHODS: We conducted a systematic literature search to
identify studies that evaluated methods used to estimate mean utilities for comor-
bidities using mean values from cohorts with the corresponding single conditions.
We extracted the preference-based utility measure used, the number and range of
estimated utility values, the baseline used to value utility decrements, the statistics
used to compare estimates, and the conclusions of the authors. RESULTS: Four of
the six studies identified used EQ-5D data, one used SF-6D and one used HUI3. One
presented the multiplicative method, one compared the additive and multiplica-
tive methods, and four compared the additive, multiplicative, and minimum meth-
ods with the results obtained from linear models. The number of mean utility
values estimated ranged from 32 to 760 and the range of actual mean values ranged
from 0.465 to 0.607 for SF-6D, to -0.01 to 1 for HUI3. Systematic errors were observed
in the values estimated using all methods. While the simple linear models pro-
duced the most accurate results these require validation. Of the other three, on
average the multiplicative method estimated the most accurate values across the
full range of actual utilities assessed. CONCLUSIONS: While additional research is
required before a particular method can be advocated, based on the current evi-
dence base we would recommend the multiplicative method is used if data are not
available from cohorts with the comorbidities.
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OBJECTIVES: The Brazilian Extended Consumer Price Index (IPCA) for Pharmaceu-
tical Products (IPCA-Pharmaceuticals) measures changes in the prices of a fixed
basket of medicines purchased by Brazilian households. Monitoring, modeling and
prediction of the index are important because adjustments for inflation must be
made in accordance with the principles of good practice in health economic anal-
yses. In addition, the index has an important weight in the calculation of the
General IPCA, the official index to guide inflation-related policies, and is used to
regulate pharmaceutical products prices. The objectives of this study are: 1) to
model the IPCA-Pharmaceuticals time series during the sample period 2006-2010;
and 2) predict the rate of inflation for the year 2011. METHODS: Two classical
methodologies of time series analysis were employed: Holt-Winters exponential
smoothing and the Box-Jenkins approach. Both methods were compared across
three statistics based on errors measures: mean squared error, mean absolute
percent error, and Theil’s U coefficient. The best fitted model was chosen based on
minimizing the error statistics and was used to forecast the IPCA-pharmaceuticals
in 2011. RESULTS: Monthly IPCA-Pharmaceuticals data was collected from July
2006 to December 2010 (n54) from Brazilian Institute of Geography and Statistics.
The IPCA-Pharmaceuticals percentage change time series was converted to index
number on base July 2006100. The Holt-Winters additive method was adjusted
and compared with a SARIMA (0,1,1)x(1,0,0)12 model estimated through the Box-
Jenkins approach. The between-methods comparison showed a large advantage
for the Box-Jenkins, which minimized the three errors measures. CONCLUSIONS:
The Box-Jenkins method presented better results as compared to the Holt-Winters
method. The final forecasting predicted a 2% inflation rate for pharmaceutical
products by the end of 2011, which is lower than the general inflation target rate
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